# Addiction Medicine Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN
- Date: 2026-06-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: modern shifted

- To: Tobias Grünewald, MD, Addiction Medicine
- Urgency: Within one week, on the same day as her one-week primary care visit

## Referral question

Long-term dependence on prescribed secobarbital and dextroamphetamine that began with pills given to her as a teenage performer, in a 33-year-old singer three months after childbirth, with depression and anxiety. Please confirm the diagnoses and advise on a safe way to withdraw the barbiturate and stop the stimulant. **S**

## Questions for the consultant

1. Does she meet criteria for sedative-hypnotic and stimulant use disorders, given that these medicines were prescribed?
2. How should the barbiturate be withdrawn safely: in hospital or as an outpatient, with which medicine, and at what pace?
3. Should the stimulant be stopped, and at the same time as the barbiturate or afterwards?
4. How should we treat her insomnia, depression and anxiety during the taper, and what should we avoid?
5. Does she need naloxone, and what monitoring do you advise?

## Pertinent history

Given stimulant and sleeping pills since her teens; for years she has taken secobarbital 200 mg at bedtime, sometimes 300 mg, and dextroamphetamine 10 mg each morning with extra tablets on long working days, from three prescribers at two pharmacies, as the prescription drug monitoring program confirms. She has tried to cut down on her own and could not sleep. No opioids, benzodiazepines or pills from outside a pharmacy; urine drug test shows barbiturates and amphetamine only. No withdrawal seizures known. DAST-10 6, AUDIT-C 2. PHQ-9 14 (item 9 scored 0), GAD-7 13, Mood Disorder Questionnaire negative; structured safety assessment shows no current suicidal thoughts; suicide attempts were reported in earlier years. Third child born three months ago; not breastfeeding; pregnancy test negative. Pulse 98, blood pressure 128/84; ECG normal. Today: prescriptions moved to this clinic alone, seven days at a time; secobarbital continued at 200 mg at bedtime and dextroamphetamine at 10 mg each morning with no extra doses; sertraline 25 mg started; medroxyprogesterone injection given; CBT for insomnia and psychotherapy arranged. Blood test results from today attached. **S**

- Judy Garland was born Frances Ethel Gumm on June 10, 1922, in Grand Rapids, Minnesota, to parents in vaudeville, and first appeared on stage as a small child. **D**
- She was signed by Metro-Goldwyn-Mayer at 13 and became a national star at 17 in The Wizard of Oz. **D**
- As a teenage studio performer she was given stimulant "pep pills" (amphetamines; Benzedrine is named) to suppress her appetite and keep up her energy through long working days, and sleeping pills (barbiturates; Seconal is named) so that she could sleep. She later described being given pills to stay on her feet and then being put to sleep with sleeping pills at the studio hospital. **D**
- Accounts differ on who first gave her the pills. A biography by Gerald Clarke reports that her mother gave her pills for energy and sleep in early childhood, before she joined the studio; other accounts attribute the pills to the studio and its doctors. **R**
- She struggled with dependence on prescribed medicines, stimulants and sleeping pills, for the rest of her life; by her twenties she was already dependent on pills. **D**
- Suicide attempts were reported publicly, including one in 1950; a biographical encyclopedia describes others in the 1940s and early 1950s. **D**
- In her twenties she was treated for what was publicly called exhaustion and spent periods in hospitals and sanitariums, including a stay at Peter Bent Brigham Hospital in Boston in 1949. **D**
- Her contract with Metro-Goldwyn-Mayer ended in 1950, and she returned to the stage in concert. **D**
- She starred in A Star Is Born, released in 1954, and was nominated for the Academy Award for Best Actress. **D**
- She gave birth to her third child, a son, in March 1955. **D**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin: 12.3 g/dL; MCV: 86 fL; Platelets: 284 10*3/uL; Ferritin: 24 ng/mL; Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.66 mg/dL; eGFR (CKD-EPI 2021): 119 mL/min/1.73 m²; Glucose: 82 mg/dL; AST: 21 U/L; ALT: 18 U/L; GGT: 24 U/L; TSH: 1.9 mIU/L; DAST-10: 6; AUDIT-C: 2; PHQ-9: 14; GAD-7: 13. All results are synthetic.

BP 128/84 mmHg; pulse 98 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 46.5 kg; BMI 20.4 kg/m². All vital signs are synthetic.

## Current medications

- Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine **S**
- Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy **S**
- Sertraline 25 mg oral tablet, one tablet daily **S**
- Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**

## Plan so far

- Safe prescribing of controlled drugs: one prescriber and one pharmacy, a prescription drug monitoring program check before every controlled-substance prescription, a written shared treatment agreement, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused capsules. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Insomnia: cognitive behavioral therapy for insomnia as first-line treatment, adapted to late performances (a fixed wake time, a wind-down routine after shows, sleep restriction only after the taper is stable), with a sleep diary; no new hypnotic. Guideline: Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016) **S**
- Depression and anxiety: PHQ-9 and GAD-7 at each visit, sertraline, weekly psychotherapy, the Mood Disorder Questionnaire before the antidepressant, a structured safety assessment with a written safety plan, means safety and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Nutrition and weight without stigma: regular meals and snacks around rehearsals, a dietitian visit, no weight-loss target and no dieting drugs, and screening for disordered eating. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Contraception that barbiturates do not weaken: medroxyprogesterone injection every 13 weeks, after a negative pregnancy test, with an intrauterine device as an alternative. Guideline: U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024) **S**
- Naloxone not prescribed: she takes no opioid, has no opioid prescription in the monitoring program, her urine test shows no opioids or fentanyl, and all her pills come from a pharmacy; naloxone does not reverse a barbiturate overdose. To be offered at once if an opioid is ever prescribed or any pill comes from outside a pharmacy. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Work: taper steps scheduled away from major performances, a written plan for late nights and travel, and letters she controls. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**
